Michael Hallek
Research Subjects
Michael Hallek has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Anne Girod
Laboratorium für Molekulare Biologie, Genzentrum, Ludwig-Maximilians-Universität München, Feodor-Lynen-Strasse 25, D-81377 München, Germany1
2 shared publicationsBarbara Schmitt
Klinikum der Universität München, Großhadern, München
2 shared publications- Clemens-Martin Wendtner
Medical Clinic III, Klinikum Grosshadern, LMU, München, Germany; Institute of Medical Statistics and Epidemiology, München, Germany; Medical Clinic I, University Hospital, Cologne, Germany
2 shared publications Kristin Leike
Laboratorium für Molekulare Biologie, Genzentrum, Ludwig-Maximilians-Universität München, Feodor-Lynen-Strasse 25, D-81377 München, Germany1
2 shared publicationsA. Engert
1 shared publicationAlexander Kröber
Abteilung für Innere Medizin III, Universität Ulm
1 shared publication
Latest Publications
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7053
Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group
7053 Background: Purine nucleoside combination therapy has become the standard treatment approach in B-CLL. In order to enhance efficacy, various combinations with monoclonal antibodies are under investigation. As alemtuzumab has proven to be the most effective antibody in CLL treatment, we developed a multicenter phase II trial combining fludarabine, cyclophosphamide and alemtuzumab in a 4-weekly schedule. Methods: Fludarabine 25mg/m2 iv, cyclophosphamide 200mg/m2 iv and alemtuzumab 30 mg sc were given on days 1 - 3 and repeated on day 29 for up to six cycles. A 2-day escalation of alemtuzumab was administered prior to the first cycle. Minimal residual disease (MRD) was measured by 4-color flow cytometry. Antiinfective prophylaxis consisted of TMP-SMZ DS twice daily 3d/wk and valacyclovir during and at least two months after completion of treatment. CMV antigen in blood was tested in 14-days intervals. Results: A total of 39 patients of a planned sample size of 61 patients were included in this phase-II study so far, of which 20 patients are evaluable for response and safety analysis. Median age is 64 (range 48–78) years with a medium number of 1 prior regimen; 14/20 patients completed at least four cycles with a median number of 4.5cycles. Pretreatment consisted of fludarabine (8/20), fludarabine and cyclophosphamide (12/20) or rituximab combination (1/20). Thrombocytopenia and neutropenia were the most serious side effects and detailed data will be presented. 2 CMV-reactivations, 1 Herpes-zoster-reactivation and 12 fever of unknown origin have been reported. The overall response rate was 70% with 5 CR (25%), 9 PR (45%), 2 SD and 2 PD. All complete responders became MRD negative in peripheral blood or bone marrow; response was independent of FISH status. A correlation of response with prior treatment was observed, with 88% ORR for fludarabine pre-treatment versus only 65% for those patients pretreated with fludarabine and cyclophosphamide. Conclusions: The concomitant application of fludarabine, cyclophosphamide and alemtuzumab appears as a safe and effective approach for patients with relapsed CLL.
- 20 May 2008
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15) , 7053
Treatment of patients with relapsed/refractory CLL using a combination of fludarabine, cyclophosphamide and alemtuzumab: First safety analysis of the CLL2L trial of the German CLL Study Group
7053 Background: Purine nucleoside combination therapy has become the standard treatment approach in B-CLL. In order to enhance efficacy, various combinations with monoclonal antibodies are under investigation. As alemtuzumab has proven to be the most effective antibody in CLL treatment, we developed a multicenter phase II trial combining fludarabine, cyclophosphamide and alemtuzumab in a 4-weekly schedule. Methods: Fludarabine 25mg/m2 iv, cyclophosphamide 200mg/m2 iv and alemtuzumab 30 mg sc were given on days 1 - 3 and repeated on day 29 for up to six cycles. A 2-day escalation of alemtuzumab was administered prior to the first cycle. Minimal residual disease (MRD) was measured by 4-color flow cytometry. Antiinfective prophylaxis consisted of TMP-SMZ DS twice daily 3d/wk and valacyclovir during and at least two months after completion of treatment. CMV antigen in blood was tested in 14-days intervals. Results: A total of 39 patients of a planned sample size of 61 patients were included in this phase-II study so far, of which 20 patients are evaluable for response and safety analysis. Median age is 64 (range 48–78) years with a medium number of 1 prior regimen; 14/20 patients completed at least four cycles with a median number of 4.5cycles. Pretreatment consisted of fludarabine (8/20), fludarabine and cyclophosphamide (12/20) or rituximab combination (1/20). Thrombocytopenia and neutropenia were the most serious side effects and detailed data will be presented. 2 CMV-reactivations, 1 Herpes-zoster-reactivation and 12 fever of unknown origin have been reported. The overall response rate was 70% with 5 CR (25%), 9 PR (45%), 2 SD and 2 PD. All complete responders became MRD negative in peripheral blood or bone marrow; response was independent of FISH status. A correlation of response with prior treatment was observed, with 88% ORR for fludarabine pre-treatment versus only 65% for those patients pretreated with fludarabine and cyclophosphamide. Conclusions: The concomitant application of fludarabine, cyclophosphamide and alemtuzumab appears as a safe and effective approach for patients with relapsed CLL.
- 1 June 2004
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 129 (25/26) , 1440-1445
Prophylaxis and differential therapy of tumorlysis syndrome
Das akute Tumorlysesyndrom ist - insbesondere bei malignen Erkrankungen mit hoher Proliferationsrate und Zellfragilität - eine bedrohliche onkologisch-internistische Notfallsituation. Obwohl das klinische Erscheinungsbild hinlänglich bekannt und beschrieben ist (12,13), sind die publizierte Literatur und die Evidenzbasis bezüglich Risikogruppen, Prävention und Therapie limitiert. Die Therapie von Hyperphosphatämie, Hypokalzämie, Hyperkaliämie und Hyperurikämie stützt sich vor allem auf supportive Maßnahmen. Mit der Zulassung von Rasburicase, einer rekombinant hergestellten Uratoxidase, ist seit kurzer Zeit eine neue Substanz für die Behandlung der Hyperurikämie im Rahmen des Tumorlysesyndroms erhältlich. Dieser Artikel ist als Empfehlung für den Umgang mit dieser neuen Substanz gedacht. Neben einer Darstellung der praktischen Erfahrungen erfolgt ein kurzer Überblick über die Literatur mit dem Versuch einer Definition von Handlungsrichtlinien für Erkennung, Prophylaxe und Therapie der akuten Tumorlyse.
- 1 June 2004
- Published by Georg Thieme Verlag KG in DMW - Deutsche Medizinische Wochenschrift
- Vol. 129 (25/26) , 1440-1445
Prophylaxis and differential therapy of tumorlysis syndrome
Das akute Tumorlysesyndrom ist - insbesondere bei malignen Erkrankungen mit hoher Proliferationsrate und Zellfragilität - eine bedrohliche onkologisch-internistische Notfallsituation. Obwohl das klinische Erscheinungsbild hinlänglich bekannt und beschrieben ist (12,13), sind die publizierte Literatur und die Evidenzbasis bezüglich Risikogruppen, Prävention und Therapie limitiert. Die Therapie von Hyperphosphatämie, Hypokalzämie, Hyperkaliämie und Hyperurikämie stützt sich vor allem auf supportive Maßnahmen. Mit der Zulassung von Rasburicase, einer rekombinant hergestellten Uratoxidase, ist seit kurzer Zeit eine neue Substanz für die Behandlung der Hyperurikämie im Rahmen des Tumorlysesyndroms erhältlich. Dieser Artikel ist als Empfehlung für den Umgang mit dieser neuen Substanz gedacht. Neben einer Darstellung der praktischen Erfahrungen erfolgt ein kurzer Überblick über die Literatur mit dem Versuch einer Definition von Handlungsrichtlinien für Erkennung, Prophylaxe und Therapie der akuten Tumorlyse.
- 10 July 2003
- Vol. 145, 46-9
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
- 10 July 2003
- Vol. 145, 46-9
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
- 1 October 2002
- Published by Springer Nature in Die Innere Medizin
- Vol. 43 (10) , 1245-1254
Chronische lymphatische Leukämie Aktuelle Therapiekonzepte
- 1 October 2002
- Published by Springer Nature in Die Innere Medizin
- Vol. 43 (10) , 1245-1254
Chronische lymphatische Leukämie Aktuelle Therapiekonzepte
- 1 May 2002
- Published by Microbiology Society in Journal of General Virology
- Vol. 83 (5) , 973-978
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity
The unique region of the VP1 protein of parvoviruses was proposed to contain a parvoviral phospholipase A2 (pvPLA2) motif. Here, PLA2 activity is shown in the unique region of adeno-associated virus type 2 (AAV-2) VP1 when expressed as an isolated domain in bacteria. Mutations in this region of the capsid protein strongly reduced the infectivity of mutant virions in comparison to wild-type AAV-2. This correlated with effects on the activity of PLA2. The mutations had no influence on capsid assembly, packaging of viral genomes into particles or binding to and entry into HeLa cells. However, a delayed onset and reduced amount of early gene expression, as measured by Rep immunofluorescence, was observed. These results suggest that pvPLA2 activity is required for a step following perinuclear accumulation of virions but prior to early gene expression.
- 1 May 2002
- Published by Microbiology Society in Journal of General Virology
- Vol. 83 (5) , 973-978
The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity
The unique region of the VP1 protein of parvoviruses was proposed to contain a parvoviral phospholipase A2 (pvPLA2) motif. Here, PLA2 activity is shown in the unique region of adeno-associated virus type 2 (AAV-2) VP1 when expressed as an isolated domain in bacteria. Mutations in this region of the capsid protein strongly reduced the infectivity of mutant virions in comparison to wild-type AAV-2. This correlated with effects on the activity of PLA2. The mutations had no influence on capsid assembly, packaging of viral genomes into particles or binding to and entry into HeLa cells. However, a delayed onset and reduced amount of early gene expression, as measured by Rep immunofluorescence, was observed. These results suggest that pvPLA2 activity is required for a step following perinuclear accumulation of virions but prior to early gene expression.
- 1 May 2002
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (9) , 4559-4566
Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors
Recombinant adeno-associated virus type 2 (rAAV2) is a promising vector for human somatic gene therapy. However, its broad host range is a disadvantage for some applications, because it reduces the specificity of the gene transfer. To overcome this limitation, we sought to create a versatile rAAV vector targeting system which would allow us to redirect rAAV binding to specific cell surface receptors by simple coupling of different ligands to its capsid. For this purpose, an immunoglobulin G (IgG) binding domain of protein A, Z34C, was inserted into the AAV2 capsid at amino acid position 587. The resulting AAV2-Z34C mutants could be packaged and purified to high titers and bound to IgG molecules. rAAV2-Z34C vectors coupled to antibodies against CD29 (β 1 -integrin), CD117 (c-kit receptor), and CXCR4 specifically transduced distinct human hematopoietic cell lines. In marked contrast, no transduction was seen in the absence of antibodies or in the presence of specific blocking reagents. These results demonstrate for the first time that an immunoglobulin binding domain can be inserted into the AAV2 capsid and coupled to various antibodies, which mediate the retargeting of rAAV vectors to specific cell surface receptors.
- 1 May 2002
- Published by American Society for Microbiology in Journal of Virology
- Vol. 76 (9) , 4559-4566
Adeno-Associated Virus Capsids Displaying Immunoglobulin-Binding Domains Permit Antibody-Mediated Vector Retargeting to Specific Cell Surface Receptors
Recombinant adeno-associated virus type 2 (rAAV2) is a promising vector for human somatic gene therapy. However, its broad host range is a disadvantage for some applications, because it reduces the specificity of the gene transfer. To overcome this limitation, we sought to create a versatile rAAV vector targeting system which would allow us to redirect rAAV binding to specific cell surface receptors by simple coupling of different ligands to its capsid. For this purpose, an immunoglobulin G (IgG) binding domain of protein A, Z34C, was inserted into the AAV2 capsid at amino acid position 587. The resulting AAV2-Z34C mutants could be packaged and purified to high titers and bound to IgG molecules. rAAV2-Z34C vectors coupled to antibodies against CD29 (β 1 -integrin), CD117 (c-kit receptor), and CXCR4 specifically transduced distinct human hematopoietic cell lines. In marked contrast, no transduction was seen in the absence of antibodies or in the presence of specific blocking reagents. These results demonstrate for the first time that an immunoglobulin binding domain can be inserted into the AAV2 capsid and coupled to various antibodies, which mediate the retargeting of rAAV vectors to specific cell surface receptors.
- Open Access
- 1 August 2001
- Published by Wiley in British Journal of Haematology
- Vol. 114 (2) , 342-348
Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group
The efficacy and toxicity of a combination of fludarabine and cyclophosphamide (FC) was evaluated in patients with B‐cell chronic lymphocytic leukaemia (CLL). Between April 1997 and July 1998, 36 patients with CLL (median age 59 years) received a regimen that consisted of fludarabine 30 mg/m2 in a 30‐min IV infusion, d 1–3, and cyclophosphamide 250 mg/m2 in a 30‐min IV infusion on d 1–3. Cycles were repeated every 28 d. Twenty‐one patients had received between one and three different treatment regimens prior to the study, while 15 patients had received no prior therapy. The median Eastern Cooperative Oncology Group performance score was 1. One patient was at Binet stage A, 18 were stage B and 17 patients were stage C. Objective responses, assessed according to the revised guidelines of the National Cancer Institute‐sponsored Working Group, were recorded in 29 out of 32 assessable patients (90·6%). Twenty‐four partial remissions and five complete remissions were observed. Two patients showed no change and one patient showed disease progression. At February 2000, three of the responders had relapsed. Severe neutropenia, anaemia and thrombocytopenia (Common Toxicity Criteria grade 3 and 4) were observed in 25, six and six patients (69·4%, 16·7% and 16·7%) respectively. Other side‐effects were uncommon. No treatment‐related deaths and no grade 3 or 4 infections occurred. We conclude that the combination of fludarabine and cyclophosphamide showed significant activity in patients with CLL. Myelosuppression was the major side‐effect. These results warrant further study on the FC combination in randomized trials.
- 1 August 2001
- Published by Wiley in British Journal of Haematology
- Vol. 114 (2) , 342-348
Open AccessFludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group
The efficacy and toxicity of a combination of fludarabine and cyclophosphamide (FC) was evaluated in patients with B‐cell chronic lymphocytic leukaemia (CLL). Between April 1997 and July 1998, 36 patients with CLL (median age 59 years) received a regimen that consisted of fludarabine 30 mg/m2 in a 30‐min IV infusion, d 1–3, and cyclophosphamide 250 mg/m2 in a 30‐min IV infusion on d 1–3. Cycles were repeated every 28 d. Twenty‐one patients had received between one and three different treatment regimens prior to the study, while 15 patients had received no prior therapy. The median Eastern Cooperative Oncology Group performance score was 1. One patient was at Binet stage A, 18 were stage B and 17 patients were stage C. Objective responses, assessed according to the revised guidelines of the National Cancer Institute‐sponsored Working Group, were recorded in 29 out of 32 assessable patients (90·6%). Twenty‐four partial remissions and five complete remissions were observed. Two patients showed no change and one patient showed disease progression. At February 2000, three of the responders had relapsed. Severe neutropenia, anaemia and thrombocytopenia (Common Toxicity Criteria grade 3 and 4) were observed in 25, six and six patients (69·4%, 16·7% and 16·7%) respectively. Other side‐effects were uncommon. No treatment‐related deaths and no grade 3 or 4 infections occurred. We conclude that the combination of fludarabine and cyclophosphamide showed significant activity in patients with CLL. Myelosuppression was the major side‐effect. These results warrant further study on the FC combination in randomized trials.
- 1 January 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 73 (1) , 32-38
New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia
Chronic lymphocytic leukemia of the B-cell type (B-CLL) is the most frequently occurring leukemia in the Western hemisphere. Until 10 years ago, the basic medical approach to this disease was expectative and palliative. Chemotherapy with alkylating agents such as chlorambucil used to be the main therapeutic option, and only patients at advanced stages of B-CLL were treated. With the advent of new treatments such as purine analogs, high-dose therapy followed by hematopoietic progenitor support, monoclonal antibodies, and further immunotherapies, this paradigm is about to change. By using these combinations, younger patients with active disease are now treated with the goal of a long-lasting remission. More sophisticated techniques allow characterization of some of the underlying molecular genetic aberrations and (together with new serum parameters) more accurate prediction of individual prognoses than with the clinical staging systems. With the help of these developments, patients with B-CLL will be managed according to their individual risk with a watch-and-wait strategy in patients with the most indolent form of the disease, conventional chemotherapy with alkylating agents and/or purine analogs in patients at intermediate risk, and aggressive high-dose chemotherapy (followed by immunotherapy) in patients with the most aggressive form of the disease.
- 1 January 2001
- Published by Springer Nature in International Journal of Hematology
- Vol. 73 (1) , 32-38
New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia
Chronic lymphocytic leukemia of the B-cell type (B-CLL) is the most frequently occurring leukemia in the Western hemisphere. Until 10 years ago, the basic medical approach to this disease was expectative and palliative. Chemotherapy with alkylating agents such as chlorambucil used to be the main therapeutic option, and only patients at advanced stages of B-CLL were treated. With the advent of new treatments such as purine analogs, high-dose therapy followed by hematopoietic progenitor support, monoclonal antibodies, and further immunotherapies, this paradigm is about to change. By using these combinations, younger patients with active disease are now treated with the goal of a long-lasting remission. More sophisticated techniques allow characterization of some of the underlying molecular genetic aberrations and (together with new serum parameters) more accurate prediction of individual prognoses than with the clinical staging systems. With the help of these developments, patients with B-CLL will be managed according to their individual risk with a watch-and-wait strategy in patients with the most indolent form of the disease, conventional chemotherapy with alkylating agents and/or purine analogs in patients at intermediate risk, and aggressive high-dose chemotherapy (followed by immunotherapy) in patients with the most aggressive form of the disease.